Metastatic urothelial carcinoma (mUC) is an advanced form of urothelial carcinoma, primarily affecting the bladder, and is known for its poor prognosis and limited treatment options. As per Dechao Feng et al., 2023, urothelial carcinoma ranks as the fourth most common tumor, with approximately 160,000 new diagnoses and 31,000 deaths annually. It accounts for a significant portion of metastatic cancers, driving the need for effective therapies. According to the metastatic urothelial carcinoma pipeline analysis by Expert Market Research, the market for metastatic urothelial carcinoma therapeutics is witnessing steady growth due to the rising focus on targeted and immunotherapy-based treatments.
Major companies involved in the metastatic urothelial carcinoma pipeline analysis include Sichuan Baili Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., and others.
Leading drugs currently in the pipeline include BL-B01D1, BT8009, TYRA-300, and others.
The metastatic urothelial carcinoma drug pipeline is expected to grow due to rising clinical trials for antibody-drug conjugates, expanded immunotherapy indications, and increased regulatory support for novel therapies.
The Metastatic Urothelial Carcinoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into metastatic urothelial carcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for metastatic urothelial carcinoma. The metastatic urothelial carcinoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The metastatic urothelial carcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with metastatic urothelial carcinoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to metastatic urothelial carcinoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Metastatic urothelial carcinoma is an advanced form of bladder cancer that originates in the urothelial cells lining the urinary tract. It occurs when cancer spreads from the bladder to distant organs such as the liver, lungs, or bones, often through the bloodstream or lymphatic system.
Metastatic urothelial carcinoma treatment includes immunotherapy, targeted therapy, and chemotherapy, often based on the patient's overall health and previous treatments received. In December 2023, the U.S. Food and Drug Administration approved the combination of enfortumab vedotin-ejfv and pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, following superior survival outcomes in the EV-302 clinical trial.
According to Dechao Feng et al., 2023, urothelial carcinoma records approximately 160,000 new cases and 31,000 deaths annually, with muscle-invasive bladder cancer comprising 25% of cases and a five-year survival rate of only 5% in metastatic stages. Florence Joly et al., 2025, reported that bladder cancer made up 4% of all cancer diagnoses in France in 2020, with 16,490 new cases. Urothelial carcinoma accounted for over 90%, highlighting the urgent need for effective drug development.
This section of the report covers the analysis of metastatic urothelial carcinoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The metastatic urothelial carcinoma pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II (at nearly 45%) covers a major share of the total metastatic urothelial carcinoma clinical trials, indicating strong ongoing research activity. Phase I holds 42%, showcasing robust early-stage development. Phase III stands at 12.22%, reflecting promising candidates nearing approval. These advancements signal potential growth and innovation in treatment outcomes.
The drug molecule categories covered under the metastatic urothelial carcinoma pipeline analysis include small molecules, monoclonal antibodies, antibody-drug conjugates, biologics, and RNA-based therapies. The metastatic urothelial carcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for metastatic urothelial carcinoma. Antibody-drug conjugates are gaining momentum in the treatment landscape of metastatic urothelial carcinoma due to their targeted mechanism of action. For example, MRG-002 by Shanghai Miracogen is currently in Phase III trials. This investigational therapy targets HER2-expressing tumors and delivers cytotoxic agents directly to cancer cells, aiming to enhance efficacy while minimizing systemic toxicity.
The EMR report for the metastatic urothelial carcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed metastatic urothelial carcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in metastatic urothelial carcinoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for metastatic urothelial carcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of metastatic urothelial carcinoma drug candidates.
BL-B01D1, developed by Sichuan Baili Pharmaceutical Co., Ltd., is a first-in-class antibody-drug conjugate (ADC) combining an EGFR×HER3 bispecific antibody with a cleavable linker and a novel topoisomerase I inhibitor. The ongoing Phase III trial is evaluating its safety and efficacy in patients with recurrent or metastatic urothelial carcinoma after failure of PD-1/PD-L1 inhibitors and platinum-based chemotherapy. This study is comparing BL-B01D1 with physician’s choice of chemotherapy.
BT8009, sponsored by BicycleTx Limited, is currently being evaluated in a global Phase 2/3 study for participants with locally advanced or metastatic urothelial cancer. This study is assessing the efficacy and safety of BT8009, alone and with pembrolizumab. BT8009 is a Bicycle Toxin Conjugate targeting Nectin-4, offering rapid tumor penetration and reduced off-target toxicity due to its low molecular weight and short plasma half-life.
TYRA-300, developed by Tyra Biosciences, Inc., is a selective oral FGFR3 tyrosine kinase inhibitor currently being evaluated in a Phase 1/2 trial for advanced or metastatic urothelial carcinoma with FGFR3 gene alterations. This study is examining the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TYRA-300. The trial is determining the optimal dosing while assessing early signs of clinical efficacy across eligible patient populations.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Metastatic Urothelial Carcinoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for metastatic urothelial carcinoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into metastatic urothelial carcinoma collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share